What's in HanAll BioPharma Co., Ltd.'s pipeline?

HanAll BioPharma Co., Ltd. has 7 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 4 in Phase 1.

Which companies overlap with HanAll BioPharma Co., Ltd.'s portfolio?

Top competitors by shared drug class: Jiangsu Alphamab Biopharmaceuticals Co., Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hanall-biopharma-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

HanAll BioPharma Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HanAll BioPharma Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
HL-040XC	HL-040XC	phase 3	Bispecific antibody; immune checkpoint inhibitor		Oncology
HL036 Ophthalmic Solution	HL036 Ophthalmic Solution	phase 3			Ophthalmology

Therapeutic area mix

Oncology · 1
Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Jiangsu Alphamab Biopharmaceuticals Co., Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for HanAll BioPharma Co., Ltd.:

Cite this brief

Drug Landscape (2026). HanAll BioPharma Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hanall-biopharma-co-ltd. Accessed 2026-05-16.